July 18, 2007

Improving Detection of Adverse Effects of Marketed Drugs

Author Affiliations

Author Affiliations: Department of Psychiatry, Columbia University, New York, New York (Dr Klein); Department of Psychiatry, University of Pennsylvania and Philadelphia VA Medical Center (Dr O'Brien).

JAMA. 2007;298(3):333-334. doi:10.1001/jama.298.3.333

Public concern about serious toxicities from marketed drugs approved by the US Food and Drug Administration (FDA) has led to suspicion of both the pharmaceutical industry and the FDA.1 This has caused the FDA to issue severe, black-box warnings about antidepressant use; however, this action may have been taken based on inadequate grounds.2

First Page Preview View Large
First page PDF preview
First page PDF preview